The firm maintained its \u2018Market Perform\u2019 rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock\u2019s closing price on Monday.<\/p>\n
Novo shares<\/a> were down about 1% in Tuesday\u2019s pre-market trade, while\u00a0Hims & Hers shares<\/a> were up nearly 5% at the time of writing. Retail sentiment around HIMS stock trended in the \u2018extremely bullish\u2019 territory on the platform.<\/p>\n Why Are Analysts Bullish On HIMS?<\/p>\n Analysts at BofA nearly doubled their price target for HIMS stock following the company\u2019s deal with Novo. The firm now has a price target of $23, up from $12.5, while the rating has been upgraded to \u2018Neutral\u2019 from \u2018Underperform\u2019.<\/p>\n The firm stated that Novo dropping its patent infringement lawsuit against Hims is a \u201cclear positive\u201d for the telehealth operator. BofA sees the risk-to-reward ratio as balanced now following the deal.<\/p>\n Deutsche Bank also hiked its price target for HIMS to $28 from $25, implying an upside of more than 26% from Monday\u2019s closing price. The firm cited the Novo deal for its price target hike, while keeping a \u2018Hold\u2019 rating on the HIMS stock.<\/p>\n What Did Novo, Hims Agree On?<\/p>\n Hims and Novo Nordisk announced a partnership to offer Ozempic and Wegovy at affordable self-pay prices on the telehealth company\u2019s platform.<\/p>\n Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. The company stated that Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg are covered. It will also include Wegovy injections in 1.7 mg and 2.4 mg doses, while Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are covered.<\/p>\n It added that these Ozempic and Wegovy offerings will be made available on its platform later this month.<\/p>\n How Did Stocktwits Users React?<\/p>\n One bullish user on Stocktwits believes selling HIMS stock at this point will be one of the \u201cbiggest mistakes\u201d of their life.\u00a0<\/p>\n Another user stated that every dip in the NVO stock is a \u201cgift.\u201dhttps:\/\/stocktwits.com\/King_of_the_bagholders\/message\/647086431<\/p>\n NVO stock<\/a> is down 22% year-to-date, while\u00a0HIMS stock<\/a> is down 32%.<\/p>\n Also See:\u00a0Iran War: Defense Secretary Hegseth Warns Of \u2018Most Intense\u2019 Strikes, Says The Middle East Country Is \u2018Badly Losing\u2019<\/a><\/p>\n For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n
![\"Add](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/02\/1771061752_645_icon-google.2109d02c.png\"){kind=icon}
<\/a><\/p>\n